Anidulafungin: a drug evaluation of a new echinocandin.
BACKGROUND
Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium.


OBJECTIVE
The intention of this review is to provide a drug evaluation of anidulafungin, including its spectrum of activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse event profile, and its role in the treatment of invasive candidiasis.


METHODS
A PubMed search was performed to gather the most current and pertinent articles.


CONCLUSIONS
Clinical trials have demonstrated anidulafungin's efficacy and tolerability in invasive candidiasis. Anidulafungin is not associated with any drug-drug interactions and does not require dosage adjustment in patients with renal and/or hepatic impairment.
Joseph
Jomy M
JM
University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA 19104, USA.
Kim
Rose
R
Reboli
Annette C
AC
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004947:Esophagus / Q000382:microbiology; D016469:Fungemia / Q000382:microbiology; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D009960:Oropharynx / Q000382:microbiology
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin